OBJECTIVES: A high prevalence of Coeliac Disease (CD) is found among patients with a clinical diagnosis of irritable bowel syndrome (IBS) compared to the general population. Symptoms of CD are quite similar to IBS, but its treatment is different. The aim of this study was to evaluate the cost-effectiveness of screening for CD in patients with diarrhoea/mixed type IBS (IBS-D/mix) in terms of cost per quality adjusted life year (QALY) in the Netherlands. METHODS: A decision model was constructed to evaluate the costs and health benefits of serological testing followed by confirmatory endoscopy with biopsy. Probabilistic sensitivity analysis (PSA) was performed to examine the effect of parameter uncertainty. Finally, the budget impact of implementing the screening process was also computed for implementation over a 10-year time horizon. RESULTS: Screening resulted in an increase of about 0.07 quality life years (QALYs) per patient over a lifetime horizon. The incremental cost effectiveness ratio was about 6,200 euro/QALY compared to no screening. The PSA showed that the uncertainty in cost effectiveness results is not considerable. The value of information analysis confirmed the robustness of the results. Screening all current patients with diarrhea/mixed type IBS would require a total budget of about 25 million Euros over a 10 year time period. CONCLUSION: Screening patients with IBS-D or IBS-mix for CD is almost certainly cost-effective. The screening program would improve the quality of life of those patients with IBS symptoms who actually have CD at a relatively low cost.
OBJECTIVES: A high prevalence of Coeliac Disease (CD) is found among patients with a clinical diagnosis of irritable bowel syndrome (IBS) compared to the general population. Symptoms of CD are quite similar to IBS, but its treatment is different. The aim of this study was to evaluate the cost-effectiveness of screening for CD in patients with diarrhoea/mixed type IBS (IBS-D/mix) in terms of cost per quality adjusted life year (QALY) in the Netherlands. METHODS: A decision model was constructed to evaluate the costs and health benefits of serological testing followed by confirmatory endoscopy with biopsy. Probabilistic sensitivity analysis (PSA) was performed to examine the effect of parameter uncertainty. Finally, the budget impact of implementing the screening process was also computed for implementation over a 10-year time horizon. RESULTS: Screening resulted in an increase of about 0.07 quality life years (QALYs) per patient over a lifetime horizon. The incremental cost effectiveness ratio was about 6,200 euro/QALY compared to no screening. The PSA showed that the uncertainty in cost effectiveness results is not considerable. The value of information analysis confirmed the robustness of the results. Screening all current patients with diarrhea/mixed type IBS would require a total budget of about 25 million Euros over a 10 year time period. CONCLUSION: Screening patients with IBS-D or IBS-mix for CD is almost certainly cost-effective. The screening program would improve the quality of life of those patients with IBS symptoms who actually have CD at a relatively low cost.
Authors: Maarten J ten Berg; Wim G Goettsch; Guido van den Boom; André J P M Smout; Ron M C Herings Journal: Eur J Gastroenterol Hepatol Date: 2006-05 Impact factor: 2.566
Authors: Hèlen Woutersen-Koch; André J P M Smout; Carla E Flik; Carel T J Hulshof; Niek J de Wit; Henriëtte E van der Horst Journal: Ned Tijdschr Geneeskd Date: 2013
Authors: Wim G Goettsch; Guido van den Boom; Nancy S Breekveldt-Postma; André J P M Smout; Ron M C Herings Journal: Pharmacoepidemiol Drug Saf Date: 2004-11 Impact factor: 2.890
Authors: Brennan Spiegel; Lucinda Harris; Susan Lucak; Emeran Mayer; Bruce Naliboff; Roger Bolus; Eric Esrailian; William D Chey; Anthony Lembo; Hetal Karsan; Kirsten Tillisch; Gareth Dulai; Jennifer Talley; Lin Chang Journal: Am J Gastroenterol Date: 2009-06-02 Impact factor: 10.864
Authors: David S Sanders; Dina Patel; Timothy J Stephenson; Anthony Milford Ward; Eugene V McCloskey; Marios Hadjivassiliou; Alan J Lobo Journal: Eur J Gastroenterol Hepatol Date: 2003-04 Impact factor: 2.566
Authors: Lauren Lapointe-Shaw; Kim L Tran; Peter C Coyte; Rebecca L Hancock-Howard; Jeff Powis; Susan M Poutanen; Susy Hota Journal: PLoS One Date: 2016-02-22 Impact factor: 3.240